Honggang M. Lou

No. 88 Jiefang Road
Hangzhou, 310009, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 49 publications

Direct background subtraction LC-MS/MS assay for human plasma progesterone: Full validation and comparative application.

Direct background subtraction LC-MS/MS assay for human plasma progesterone: Full validation and comparative application.

Journal: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences

Published: May 21, 2026

Safety, tolerability, pharmacokinetics, and pharmacodynamics of SHR8554, a biased µ-opioid receptor agonist: a phase I trial in healthy volunteers.

Safety, tolerability, pharmacokinetics, and pharmacodynamics of SHR8554, a biased µ-opioid receptor agonist: a phase I trial in healthy volunteers.

Journal: BMC pharmacology & toxicology

Published: February 14, 2026

A randomized phase III clinical trial of weekly versus tri-weekly cisplatin-based chemoradiotherapy for locally advanced cervical cancer: results of the TACO (GCIG/KGOG 1027/THAI 2012) study.

A randomized phase III clinical trial of weekly versus tri-weekly cisplatin-based chemoradiotherapy for locally advanced cervical cancer: results of the TACO (GCIG/KGOG 1027/THAI 2012) study.

Journal: ESMO open

Published: November 18, 2025

Physiologically Based Pharmacokinetic Model of Brigatinib in Healthy Volunteers and Patients With Cancer.

Physiologically Based Pharmacokinetic Model of Brigatinib in Healthy Volunteers and Patients With Cancer.

Journal: CPT: pharmacometrics & systems pharmacology

Published: October 30, 2025

Progress of coproporphyrin as an endogenous biomarker for transporter-mediated drug-drug interactions.

Progress of coproporphyrin as an endogenous biomarker for transporter-mediated drug-drug interactions.

Journal: Frontiers in pharmacology

Published: October 27, 2025

Bulumtatug Fuvedotin (BFv, 9MW2821), a next-generation Nectin-4 targeting antibody-drug conjugate, in patients with advanced solid tumors: a first-in-human, open-label, multicenter, phase I/II study.

Bulumtatug Fuvedotin (BFv, 9MW2821), a next-generation Nectin-4 targeting antibody-drug conjugate, in patients with advanced solid tumors: a first-in-human, open-label, multicenter, phase I/II study.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: February 13, 2025

Mechanisms of low MHC I expression and strategies for targeting MHC I with small molecules in cancer immunotherapy.

Mechanisms of low MHC I expression and strategies for targeting MHC I with small molecules in cancer immunotherapy.

Journal: Cancer letters

Published: September 26, 2024

Phase I clinical trial evaluating the safety, tolerance, pharmacokinetics and pharmacodynamics of HSK21542 injection in healthy volunteers.

Phase I clinical trial evaluating the safety, tolerance, pharmacokinetics and pharmacodynamics of HSK21542 injection in healthy volunteers.

Journal: Basic & clinical pharmacology & toxicology

Published: June 20, 2024

Population pharmacokinetic analysis of febuxostat with high focus on absorption kinetics and food effect.

Population pharmacokinetic analysis of febuxostat with high focus on absorption kinetics and food effect.

Journal: BMC pharmacology & toxicology

Published: April 05, 2024

Translate Pharmacokinetics of PD-1/PD-L1 Monoclonal Antibodies from Cynomolgus Monkey to Human: Comparison of Different Approaches.

Translate Pharmacokinetics of PD-1/PD-L1 Monoclonal Antibodies from Cynomolgus Monkey to Human: Comparison of Different Approaches.

Journal: Journal of pharmaceutical sciences

Published: March 11, 2024

Physiologically based absorption modeling to predict the bioequivalence of two apixaban formulations.

Physiologically based absorption modeling to predict the bioequivalence of two apixaban formulations.

Journal: Clinical and translational science

Published: March 01, 2024

Bioequivalence Study of Epalrestat for Healthy Chinese Subjects.

Bioequivalence Study of Epalrestat for Healthy Chinese Subjects.

Journal: Clinical pharmacology in drug development

Published: September 20, 2023

Showing 1-12 of 49

Last Updated: 09/26/2026